MedTrace Logo

Ipratropium Spray for Drooling Saliva in Parkinson's Disease

NCT00296946 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-02-20

No results posted yet for this study

Summary

A phase II double blind clinical trial investigating the effects of ipratropium spray versus placebo spray in patients with Parkinson's disease.

Conditions

Interventions

DRUG

ipratropium bromide (drug)

Sponsors & Collaborators

  • Parkinson's Disease Foundation

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Susan H Fox, MRCP, PhD · University Health Network, Toronto, Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Completion
2006-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00296946 on ClinicalTrials.gov